… 85% to 90% of EGFR mutations, are the EGFR exon 19 deletion that eliminates a … mutations
associated with response to erlotinib or gefitinib, we developed an assay for EGFR exon 19 …

… EGFR TKI between patients with exon 19 deletions and L858R mutations have not been …
gefitinib or erlotinib with EGFR tumor genotype (exon 19 deletion vs. L858R mutation in exon 21…

… either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib
(n = 228) or erlotinib (… , where 121 pairs of gefitinib-treated and erlotinib-treated patients were …

… had a coexisting mutation, L858R in exon 21, in addition to exon 20 mutations (Table 2). …
from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. …

… with common (exon 19 deletions and exon 21 p.Leu858Arg) and rare EGFR mutations. A …
) and rare (n=13) EGFR mutations treated with erlotinib (n=98), gefitinib (n=66) and afatinib (…

… , P=0.022) than those with exon 21 mutations treated with erlotinib or gefitinib, similar to
the … patients with EGFR exon 19 deletions than in those with exon 21 L858R mutations (Jackman …

… /or insertion in exon 20, and substitutions for L858 or L861 in the activation loop in exon 21.
As … , can detect major mutations such as L858R and deletions in exon 19, and less common …

… NSCLC shows a promising response to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) such as gefitinib and erlotinib, which target the molecular pathways of …

… Mutations occur within EGFR exons 18–21. Nearly 85%–90% of lung adenocarcinoma
patients with EGFR mutations will have in-frame deletions in exon 19 (Del19) or exon 21 …

… , suggesting that the presence of these mutations may be a predictor of response to gefitinib
… tumor mutations with an exon 19 deletion or an exon 21 (L858R) substitution mutation. …